Mulligan, bortezomib monotherapy in myeloma

Download the file

Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Gene expression profile of purified myeloma samples that were collected prior enrolment in clinical trials of bortezomib (PS-341). Samples were subject to replicate gene expression profiling using the Affymetrix 133A/B microarray. Data was normalized using MAS5.0


Information about this file
GenomicScape ID GS-DT-52
Species Homo sapiens
Cell types Multiple Myeloma
Study types Gene expression by array
Plateform/chip Affymetrix Human Genome U133 A/B
Normalization MAS5
Number of samples 264
Grouping factors cell_subpopulations; treatment; response; responder; TC_Class_2006; sex
Continuous factors Age_at_Randomization
albumin
meanMyelScore
Mayo_Clinic_ProliferativeIndex
Alternative_Therapy
C_Reactive_Protein
Beta2_Microglobulin
Survival data OS|OS_DAYS|Overall survival::PROGRESSION|DAYS_TO_PROGRESSION|Progression free survival
External database Name: GEO | ID: GSE9782 | Link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9782
Citations Mulligan G, Mitsiades C, Bryant B, Zhan F et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007 Apr 15;109(8):3177-88.
Organization Millennium Pharmaceuticals
Contact Name: George Mulligan; Department: Clinical Development; Institute: Millennium Pharmaceuticals; Address: 35 Landsdowne Stree; City: Cambridge; State: MA; Zip/postal_code: 02139; Country: USA
File name code homo-sapiens_multiple-myeloma_gene-expression-by-array_affy-hg-u133ab_mas5_GSE9782_GS-DT-52_2015-07-17
SuperSeries
Size 29.69 Mb
Upload date 07/17/15
Publication date 07/17/15
Date of release or last update 07/17/15
Downloaded
Number of views 2507 times